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Background 
Approximately 170 million people globally are infected by hepatitis C virus 
(HCV). In 2013, 17 000 patients were estimated to be HCV infected in 
Denmark. Only half of them have been diagnosed (1).  HCV may cause liver 
cirrhosis and other liver-related complication such as hepatocellular carcinoma 
(HCC), which is the leading cause of liver transplants in the United States. (2, 
3, 4, 5) 
Of the six HCV genotypes, genotype 1 is the most common, but also the most 
difficult to eradicate by therapy (8, 9). In 2011, boceprevir (BOC), one of the 
first protease inhibitors, was approved for treatment of HCV genotype 1 
infection in previously untreated and treated patients. 
 
Objectives 
The aim of this study was to evaluate the cost-effectiveness of boceprevir 
therapy in combination with pegylated interferon plus ribavirin (PEG+R), 
compared to PEG+R therapy alone, genotype 1 HCV patients, including 
treatment naïve as well as treatment experienced patients.  
 
Methods 
A Markov model simulating antiviral therapy and disease progression was 
developed to estimate lifetime healthcare costs and clinical outcomes of 
alternative treatment strategies. The model simulated the treatment regimens 
of dual therapy (PEG+R) and triple therapy (PEG+R+BOC), respectively, as 
recommended in the summary of product characteristics (SPC) and the Danish 
treatment guidelines. Data on clinical efficacy was taken from phase III 
clinical trials (SPRINT-2 and RESPOND-2).  
The model projected the expected lifetime healthcare costs and clinical 
outcomes in quality-adjusted life years (QALY). 
Costs were measured in 2012 Danish kroner (DKK) and clinical outcomes in 
(QALYs). Both costs and QALYs were discounted at 3 % per year. 
Incremental cost-effectiveness ratio (ICER) was estimated for treatment naïve 
and experienced patients in comparison with PEG+R-based therapy. 
Deterministic and probabilistic sensitivity analyses (PSA) on clinical inputs, 
costs, health state utility values, and sustained virologic response (SVR) rates 
were performed to assess the overall decision uncertainty. 
 
Figure 1. Boceprevir treatment duration and futility rules as recommended by 
SpC 
 
*futility rules: discontinue all three treatments if patients have HCV_RNA >= 
100 IU/ml at week 12 of detectable viral load week 24. Viral load test week 4 
(optional). Addition of boceprevir at start of week 5. For patients with 
cirrhosis (both treatment naïve and treatment experienced) and historical null 
responders recommended dosing: - 4 week PR lead in followed by 44 week 
tri-therapy with boceprevir PEG+ R. 
 
 
 
Figure 2 Model Structure 
 
Model inputs  
All patient characteristics were based on information for the Danish database 
InfCare hepatitis database. (table 1). Treatment related parameters were 
estimated from SPRINT-2 and RESPOND-2. Information of the probability of 
receiving liver transplant was estimated from the Nordic liver transplant 
register (table 2).  All health states and treatment related quality of life weights 
were obtained from previously published studies (table 3). Health state costs 
were based on previously published studies as well as DRG-tarifs (table 4). 
 
Table 1 Patient characteristic (8) Untrea Treated 
Gender (%)   
   Male 73 73 
   Female 27 41 
Mean age, years (SD) 50 (12) 52 (10) 
Race (%)   
Caucasian  99 99 
Black 1 1 
Baseline METAVIR Score (%)   
    F0 24 10 
    F1 43 27 
    F2 7 24 
    F3 6 13 
    F4 20 27 
 
Table 2 Annual Transition probabilities  Baseline (range) 
Fibrosis progression by use of Metavir score  
   F0 to F1 0.117 (0.104–0.130) 
   F1 to F2 0.085 (0.075–0.096) 
   F2 to F3 0.120 (0.109–0.133) 
   F3 to F4 0.116 (0.104–0.129) 
Cirrhosis progression  
   Compensated cirrhosis to decompensated 0.029 (0.010–0.039) 
   Cirrhosis to HCC (5) 0.028 (0.010–0.079) 
   Decompensated cirrhosis to HCC (9) 0.068 (0.030–0.083) 
Probability of Receiving a Liver Transplant  
  Decompensated cirrhosis (10) 0.015 (0.010–0.062) 
   HCC (10) 0.006 (0-0.04) 
Probability of moving from SVR to:   
   Decompensated cirrhosis (10) 0.010 (0.002–0.036) 
   HCC (10) 0.006 (0.002–0.013) 
Mortality Rates  
   All-cause mortality (11) age/gender specific 
   Liver-related mortality associated with 0.182 (0.065–0.190) 
   Liver-related mortality associated with 0.112 (0.065–0.190) 
Liver-related mortality associated with HCC 0.427 (0.330–0.860) 
Liver transplant (first year) 0.116 (0.060–0.420) 
Liver transplant (subsequent years) 0.044 (0.024–0.110) 
 
 
Table 3. Utility Weights Baseline (range) 
Baseline utility weights for general  
Anti-viral drug therapy-related  
 Peginterferon + ribavirin, no side 0.85 * (baseline fibrosis-stage utility) 
Peginterferon + ribavirin + 0.85 * (baseline fibrosis-stage utility) 
Anti-Viral-related anemia  (0.83*0.85)*(baseline fibrosis-stage 
Post treatment  
Sustained virologic response (cured) 0.83 (0.77–0.90) 
Health state utility weights  
   F0 0.76 (0.68–0.83) 
   F1 (14) 0.76 (0.68–0.83) 
   F2 (14) 0.76 (0.68–0.83) 
F3 (14) 0.76 (0.68–0.83) 
Compensated cirrhosis 0.74 (0.66–0.83) 
Decompensated cirrhosis (first year) 0.66 (0.46–0.86) 
Decompensated cirrhosis 0.66 (0.46–0.86) 
Hepatocellular carcinoma 0.65 (0.44–0.86) 
Liver transplant (first year) 0.69 (0.62–0.77) 
Liver transplant (subsequent years) 0.69 (0.62–0.77) 
Discount rate 3% 
 
Table 4 Economic Inputs (DKK) Baseline 
Anti-viral drug therapy-related costs (weekly)  
   Ribavirin + Peginterferon (15) 2 002 
   Boceprevir (15) 6 078 
   Erythroprotein (to treat anemia) 0 
   Monitoring Costs [i] 239 
Health state costs (annual)  
   F0 (16) 2 850 
   F1(16) 2 850 
   F2 (16) 2 850 
   F3 (16) 2 850 
Compensated cirrhosis (17) 13 600 
Decompensated cirrhosis (first year) (17) 47 050 
Decompensated cirrhosis (subsequent years) (17) 47 050 
Hepatocellular carcinoma (first year) (17) 62 040 
Hepatocellular carcinoma (subsequent years) (17) 2 850 
Liver transplant (first year) (17) 865 253 
Liver transplant (subsequent years) (17) 61 306 
Discount Rate for future costs(17) 3% 
Time Horizon Lifetime 
 
Results 
The ICER for PEG+R+BOC therapy versus standard therapy with PEG+R 
was DKK 241,774 for treatment naïve HCV patients and DKK 98,371 for 
treatment experienced patients. PSA for treatment naïve patients showed a 
probability of cost-effectiveness of PEG+R+BOC therapy compared to 
PEG+R of more than 65 % at a willingness-to-pay threshold of DKK 300,000 
(approx. £30,000). 
 
Table 5 Result 
Treatment naive 
Incremental 
costs 
Incremental 
QALY 
ICER's 
DKK 
Overall BOC vs Peg/R 123,614 0.51 242,380 
F0-F3 BOC vs PEG/R 109,493 0.62 176,602 
F4 BOC vs PEG/R 181,225 0.1 1,812,250 
Treatment experienced     
Overall BOC vs Peg/R 133,271 1.36 97,993 
F0-F3 BOC vs PEG/R 131,333 0.86 152,713 
F4 BOC vs PEG/R 138,638 2.72 50,970 
NR BOC vs PEG/R 145,623 0.87 167,383 
 
Figure 3 Results of PSA for tr eatment naive 
:  
Figure 4: Results for Treatment – Experienced
 
Conclusions 
From a Danish health economical perspective PEG+R+BOC therapy is cost 
effective in HCV genotype 1 patients to eradicate virus and to prevent 
development of late liver manifestations, such as cirrhosis and hepatocellular 
carcinoma (HCC) irrespectively of previous treatment status. 
The result was robust to changes in the model as demonstrated by the 
sensitivity analyses. 
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